RECOMMENDATIONS made by the Pharmaceutical Benefits Advisory Committee (PBAC) in December 2016 relating to the listing of drugs on the Pharmaceutical Benefits Scheme (PBS) relate to AbbVie's Humira (adalimumab), Aspen's Chlorsig (chloramphenicol eye drops) and Novartis' Certican (everolimus).
Other drugs named for listing changes were Pfizer's Nitrostat (glyceryl trinitrate sublingual tabs), Phebra's Prenoxad (naloxone injection) and Roche's Esbriet (pirfenidone caps) to be newly listed for the treatment of idiopathic pulmonary fibrosis under certain conditions - tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 31 Jan 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Jan 17
